Neurosoft Bioelectronics has become the inaugural partner under an agreement with Science Corporation that gives the brain computer interface (BCI) technology company the ability to develop products using Science’s neural recording technology stack via the company’s BCI ecosystem.
Neurosoft is developing soft electrodes to interface with the brain and provide stimulation to address conditions such as chronic pain and epilepsy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Elaborating on the partnership’s aims, Neurosoft CEO Nicolas Vachicouras said: “This partnership with Science is a strategic move that aggressively accelerates clinical adoption, bringing potentially life-changing therapies to patients faster than ever seen before in the industry, while rapidly scaling the high-fidelity neural data collection essential for powering Neurosoft’s foundation AI models.”
According to Science, developing a full-stack clinical-grade BCI platform can cost upwards of $100m. Launched in 2024, the company’s BCI ecosystem has been designed to give industry peers access to the tools necessary to “collect, process, and analyse” neural BCI data and advance their products’ clinical development quicker. The company says this can be done for around a twentieth of the standard cost.
“Neurosoft is the ideal partner to debut this model,” said Darius Shahida, Science’s chief strategy officer. “This partnership reflects Science’s broader vision to foster a community of BCI innovators working toward life-changing therapies for neurological injury and disease, and to advance the field by reducing development cost and complexity.”
Shahida added that the partnership is a “multiyear” and “multimillion-dollar” agreement, yet did not disclose any specifics.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataScience’s BCI ecosystem tools include Science Nexus, a software framework for defining and running behavioural experiments, and Synapse, a standardised API managing communication protocols for BCI products such as closed-loop neuromodulation systems and retinal visual protheses.
Science CEO Max Hodak commented: “By providing robust, modular building blocks designed to meet the requirements of the most rigorous modern BCI applications, we are enabling innovation leaders across the BCI industry to develop targeted therapeutic solutions without rebuilding fundamental infrastructure, ultimately bringing transformative therapies to patients faster.”
According to GlobalData analysis, the global neurology devices market is projected to reach a valuation above $25bn in 2034.
In healthcare, BCI technologies are on a rapid growth course. Morgan Stanley estimates there to be an early total addressable market (TAM) of $80bn across three million US adults for BCI technology, potentially reaching $320bn with further advancements.
While other major players in the technology industry, such as OpenAI, are eyeing up the BCI space, it has predominantly gained widespread attention due to Neuralink. In July 2025, reports emerged that the company, which is helmed by serial entrepreneur Elon Musk, expects to gain US Food and Drug Administration (FDA) approval for Telepathy, a BCI implant designed to give paralysed individuals the ability to control hardware such as computers and robotic limbs using only their thoughts, by 2029. By 2031, the company hopes to generate $1bn in revenue, following the implantation of Telepathy and other of its BCI implants in 20,000 patients.
